Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.45 |
| ▸ | TYK2 | P29597 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476464 | 0.87 | SYK (0.47) | SYKTYK2JAK2CCNE1CDK2 | |
| SCHEMBL18499161 | 0.84 | TYK2 (0.38) | SYKTYK2JAK2CCNE1CDK2 | |
| SCHEMBL18499163 | 0.84 | TYK2 (0.38) | SYKTYK2JAK2CCNE1CDK2 | |
| SCHEMBL2475810 | 0.83 | SYK (0.44) | SYKTYK2JAK2CCNE1CDK2 | |
| SCHEMBL2474068 | 0.82 | JAK2 (0.47) | SYKTYK2JAK2CCNE1CDK2 | |
| SCHEMBL2474769 | 0.81 | MAP3K11 (0.49) | SYKTYK2CCNE1CDK2GRIA1 | |
| SCHEMBL13288359 | 0.81 | SYK (0.59) | SYKJAK2 | |
| SCHEMBL18498989 | 0.80 | CCND3 (0.41) | SYKTYK2JAK2CDK2LYN | |
| SCHEMBL2478695 | 0.78 | SYK (0.42) | SYKLYNSRC | |
| SCHEMBL2897014 | 0.69 | SYK (0.65) | SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567348-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-14 | — | — | US | claimed |
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2015-09-24 | — | — | US | claimed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | claimed |
| EP-2373318-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | claimed |
| EP-3552607-A2 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3552607-A2 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10093684-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2017-05-04 | — | — | US | disclosed |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2017-05-04 | — | — | US | disclosed |
| US-8440667-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2373318-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | disclosed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | disclosed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885TYK2 8/4885JAK2 16/4885 |
| US-10093684-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | SYK, BTK, ZAP70 | SYK 1/4885TYK2 9/4885JAK2 13/4885 |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | SYK 1/4885TYK2 11/4885JAK2 18/4885 |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885TYK2 8/4885JAK2 16/4885 |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885TYK2 8/4885JAK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.